In today’s high-risk corporate environment, it's crucial for CFOs to understand their directors and officers insurance policy to best protect the leadership team and board.
Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to preliminary ...